OncoBench

The 4baseCare TARGT CGP Kit (RUO) is a well-validated comprehensive genomic profiling solution designed to identify genomic alterations such as single nucleotide variations (SNVs), indels, and copy number variants (CNVs) across a wide range of solid cancers. This kit is developed by experts to deliver molecular insights from cancer patient samples, focusing on therapeutic, prognostic, and diagnostic biomarkers through a single assay, ensuring efficiency and speed.

The kit includes reagents for hybridization-based library preparation, allowing for target enrichment and library creation even with low sample input. It is compatible with various sample types, including DNA, FFPE, fresh frozen, and plasma, and is effective with low-quality samples.

The OncoBench platform supports data analysis and reporting needs, enabling quality control and providing expert customer support for test setup and result security.

Features & Benefits

• Extensive analytical and clinical validation for genomic alterations in over 28 cancer types from different tissue sources, including solid tissue and liquid biopsy.
• Target genomic alterations and mutational signatures.
• Uniquely designed DNA-Seq panels with four hotspot fusions: ALK, ROS1, RET, and MET exon 14.
• Highly specific and sensitive assay with flexible integration with NGS sequencing.
• Cost and time-effective solution.

Workflow

The workflow involves several key steps: sample collection, nucleic acid extraction, library preparation and TARGT enrichment, sequencing, bioinformatics analysis using OncoBench, and variant prioritization to derive clinical insights. The TARGT assays are designed to provide an edge to the scientific and clinical community by targeting the coding regions of genes with approximately 15 probes per gene, ensuring adequate coverage and increased efficacy for low sample inputs.

The bioinformatics analysis is supported by a well-validated pipeline to identify low-frequency variants, utilizing the OncoBench tool for efficient data analysis. Clinical insights are aggregated and curated based on professional guidelines (ACMG/AMP/ASCO/ESMO) using scientific information, multiple databases, and an in-house developed population-specific database of over 3500 pan-cancer patients.

Performance Metrics

The TARGT CGP Kit (RUO) has achieved clinical maturation through extensive validation, demonstrating high specificity, sensitivity, accuracy, precision, and reproducibility across both solid and liquid biopsies. The limit of detection is 5% for SNVs and 10% for indels, with positive predictive value (PPV) and negative predictive value (NPV) metrics indicating robust performance.

OncoBench offers a 360-degree solution for scientists and healthcare professionals to identify significant biomarkers and generate comprehensive clinical reports securely, time-efficiently, and cost-effectively.